Relay Therapeutics, INC Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 10.0% of Relay Therapeutics Inc.'s common stock as of July 31, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 9.4% of Relay Therapeutics' common stock as of June 30, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in Relay Therapeutics, Inc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported beneficial ownership of 438,471 shares, representing 9.99% of Kiora Pharmaceuticals, Inc.'s common stock, following a private placement.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Relay Therapeutics Inc. following an internal realignment.

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a 5.3% beneficial ownership stake in Relay Therapeutics, Inc.

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in Relay Therapeutics, Inc., holding 17,000,000 shares of common stock.

Commodore Capital LP and its affiliates reported a 7.8% beneficial ownership stake in Relay Therapeutics, Inc., holding 13,350,000 shares of common stock as of June 30, 2025.

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen have disclosed a shared beneficial ownership of 7.8% in Relay Therapeutics, Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting a beneficial ownership of 5.47% in Relay Therapeutics Inc.'s common stock.

Commodore Capital LP and Commodore Capital Master LP have reported a passive beneficial ownership of 5.8% in Relay Therapeutics, Inc., totaling 10,000,000 shares of common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 7.14% beneficial ownership stake in Relay Therapeutics Inc., held for ordinary course investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Relay Therapeutics, Inc. as of March 31, 2025.

Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a 5.7% passive ownership stake in biotechnology firm Relay Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting an 8.8% beneficial ownership stake in Relay Therapeutics, Inc. as of December 31, 2024.